Eye Therapy News
2 Lazy 2 Run? We’re biking it for blood cancer!
Fri, 29 Aug 2014 09:30:05 +0000
On Sunday 31 August a group of not so elite athletes from the Gene and Cell Therapy group will be taking part in the London Bikeathon 2014 to raise funds for Leukaemia & Lymphoma Research. The 2 Lazy 2 Run CC will be cycling 52 miles – that’s more than a marathon, no mean feet […]Read more...
The Art of Eyes
Thu, 07 Aug 2014 14:23:19 +0000
The eye is an object of great beauty as shown by the Ophthalmologist in their July/August 2014 issue. This month’s issue features a photo essay called The Art of the Eyes and includes examples of the work from a number research labs capturing the complex and beautiful detail of the eye and its cells. The essay includes images […]Read more...
Tue, 05 Aug 2014 16:02:34 +0000
Dr Yoshiki Sasai (1962 – 2014) It is with great sadness today that we remember and pay tribute to our collaborator Dr Yoshiki Sasai. Yoshiki was a world leading stem cell researcher and Deputy Director of the Riken Center for Developmental Biology in Kobe, Japan. Through his hard work and dedication over many years, Yoshiki […]Read more...
International Clinical Trials Day: Our Work in Summary
Tue, 20 May 2014 15:03:41 +0000
Introduction Today, 20 May 2014, is International Clinical Trials Day. This landmark day remembers the pioneering work of James Lind a Scottish naval physician who, in the 1700s, conducted the first controlled clinical study that identified that citrus fruit (containing Vitamin C) was effective in treating scurvy. Each year, a number of organisations mark this […]Read more...
Gene and cell therapies for age-related macular degeneration (AMD) and diabetic eye disease
Gene therapy to control the damaging growth of blood vessels
Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. JWB Bainbridge, A Mistry, M De Alwis, E Paleolog, A Baker, AJ Thrasher and RR Ali Gene Ther. 2002; 9 (5): 320-326
EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. KS Balaggan, K Binley, M Esapa, Re MacLaren, S Iqball, Y Duran, RA Pearson, O Kan, SE Barker, AJ Smith, JWB Bainbridge, S Naylor and RR Ali Gene Ther. 2006; 13 (15):1153-1165
Models of disease
Differential modulation of retinal degeneration by Ccl2 and Cx3cr1 chemokine signalling. UF Luhmann, CA Lange, S Robbie, PM Munro, JA Cowing, HE Armer, V Luong, LS Carvalho, RE MacLaren, FW Fitzke, JW Bainbridge and RR Ali PLoS One 2012; 7 (4): e35551
The Drusen-like phenotype in aging Ccl2 knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. UF Luhmann, S Robbie, PM Munro, SE Barker, Y Duran V Luong, FW Fitzke, J Bainbridge, RR Ali & R MacLaren. Invest Ophthalmol Vis Sci. 2009; 50 (12): 5934-43
Von Hippel-Lindau protein in the RPE is essential for the normal ocular growth and vascular development. CAK Lange, UFO Luhmann, FM Moway, EL West, H Sayed, AJ Smith, JC Sodewn, PH Maxwell, RR Ali and JW Bainbridge Development 2012; 139 (13): 2340-50
HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia. FM Mowat, UF Luhmann, AJ Smith, C Lange, Y Duran, S Harten, D Shukla, PH Maxwell, RR Ali and JW Bainbridge. PLoS One 2010; 5 (6): e11103
Clinical disease mechanisms
distribution in advanced poliferative diabetic retinopathy.
CA Lange, P Stavrakas, UF Luhmann, DJ de Silva, RR Ali, ZJ Gregor & JW Bainbridge Am J Ophthalmol. 2011;152 (3): 406-412
Page last modified on 22 oct 12 15:23